Zelda Therapeutics Ltd (ASX: ZLD, US OTC: ZLDAF, Zelda or the Company) is pleased to provide an update on its previously announced paediatric brain cancer research project with the prestigious Telethon Kids Institute (“TKI” or “the Institute) in Perth, Western Australia. PAEDIATRIC BRAIN CANCER RESEARCH UPDATE
From the outside, Australia’s attitude to medicinal cannabis looks quite modern. We were one of the first countries in the world to make it legal at a federal level, and its usage for treating illness has been championed by numerous patient groups and public campaigns. ‘Medicinal cannabis: Australia isn’t as progressive as it may seem” – By Dr. Stewart Washer
Zelda Therapeutics Limited (ASX: ZLD, OTCQB: ZLDAF, “the Company” or “Zelda”) is pleased to announce that the company’s ordinary shares have been approved for trading on the OTCQB Venture Market (OTCQB) in the United States of America under the symbol “ZLDAF.” ASX Announcement: Shares Begin Trading in the USA on the OTCQB Venture Market
Meet Kara, who suffers from autism. Kara’s parents have treated her with medical cannabis to relieve her symptoms and improve her quality of life. Zelda’s research into the effect of medical cannabis on children suffering from autism, hopes to open up the potential use of cannabinoids as a safe, effective and affordable treatment option for patients in need. Meet Kara:…
‘Medical Cannabis: The current and future investment market’ – by Dr. Stewart Washer
Medical Cannabis for Autism
ASX Announcement: Successful Results in Autism Observation Trial
ASX Announcement: Update on Research Programme in Chile
ASX Announcement: Zelda’s Annual Report for the Year Ended 30 June 2017
ASX Announcement: Company Presentation on 2017 Half Year Activities